Skip to main content
FDA expands use of Thermo Fisher's BRAHMS PCT assay
7/19/2017

The FDA has given Thermo Fisher Scientific business BRAHMS 510(k) clearance for expanded use of its procalcitonin-sensitive Kryptor assay as a tool for antibiotic stewardship in intensive care, emergency departments and other hospital units. The assay, which was previously cleared for clinical use, is also intended to facilitate clinicians' decision-making on the initiation of antibiotic therapy for patients with confirmed or suspected lower-respiratory-tract infections.

Full Story: